PEARL III: SVR ≥99% After 12 Wks of ABT-450/r/267 + ABT-333 ± RBV in Treatment Naïve HCV GT1b Infection

Authors
Category Primary study
JournalTopics in Antiviral Medicine
Year 2014
This article has no abstract
Epistemonikos ID: a7b149f3f5f5280176ae4d98a86f15dd4376622b
First added on: Feb 06, 2025